AR128031A1 - Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden - Google Patents

Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden

Info

Publication number
AR128031A1
AR128031A1 ARP220103506A ARP220103506A AR128031A1 AR 128031 A1 AR128031 A1 AR 128031A1 AR P220103506 A ARP220103506 A AR P220103506A AR P220103506 A ARP220103506 A AR P220103506A AR 128031 A1 AR128031 A1 AR 128031A1
Authority
AR
Argentina
Prior art keywords
antibodies
ltbr
agonist
bispecific
antigen
Prior art date
Application number
ARP220103506A
Other languages
English (en)
Inventor
Roberta Bianchi
Felix Bormann
Michelle Victoria Brydon
Stefan Dengl
Harald Duerr
Guy Georges
Lydia Jasmin Hanisch
Monika Heidrich
Ralf Hosse
Leo Frederik Kunz
Stephane Leclair
Desire Leisibach
Fanny Mende
Olaf Mundigl
Miroslav Nikolov
Pablo Umaa
Cornelia Wagner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR128031A1 publication Critical patent/AR128031A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a novedosos anticuerpos que se unen al receptor de linfotoxina b (LTBR) y a moléculas de unión a antígeno biespecíficas que comprenden estos novedosos anticuerpos anti-LTBR y un dominio de unión a antígeno que se une a un antígeno asociado a un tumor, en particular a la proteína de activación de fibroblastos (FAP), a procedimientos de producción de estas moléculas y a procedimientos de uso de las mismas.
ARP220103506A 2021-12-20 2022-12-19 Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden AR128031A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21215804 2021-12-20
EP22208828 2022-11-22

Publications (1)

Publication Number Publication Date
AR128031A1 true AR128031A1 (es) 2024-03-20

Family

ID=84901289

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103506A AR128031A1 (es) 2021-12-20 2022-12-19 Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden

Country Status (10)

Country Link
KR (1) KR20240122864A (es)
AR (1) AR128031A1 (es)
AU (1) AU2022423749A1 (es)
CO (1) CO2024008179A2 (es)
CR (1) CR20240246A (es)
IL (1) IL313258A (es)
MX (1) MX2024007314A (es)
PE (1) PE20241754A1 (es)
TW (1) TW202340248A (es)
WO (1) WO2023117834A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU757627B2 (en) 1997-06-24 2003-02-27 Genentech Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
DK1151010T3 (da) 1999-02-05 2006-01-09 Therapeutic Human Polyclonals Humane polyklonale antistoffer fra antigene ikke-humane dyr
JP2003505082A (ja) 1999-07-26 2003-02-12 ジェネンテック・インコーポレーテッド 新規なポリヌクレオチドとその使用法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
AU2001284703B2 (en) 2000-08-03 2007-03-22 Therapeutic Human Polyclonals Inc. Production of humanized antibodies in transgenic animals
ES2335861T3 (es) 2000-09-08 2010-04-06 Universitat Zurich Grupos de proteinas repetitivas que comprenden modulos repetitivos.
CN1547590A (zh) 2000-10-13 2004-11-17 ¸ 人源化抗-LT-β-R抗体
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
TW200416044A (en) * 2002-07-01 2004-09-01 Biogen Inc Humanized anti-lymphotoxin β receptor antibodies
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
US7993650B2 (en) 2003-07-04 2011-08-09 Affibody Ab Polypeptides having binding affinity for HER2
MXPA06000562A (es) 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
SG10202008722QA (en) 2003-11-05 2020-10-29 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN101084317A (zh) 2004-10-22 2007-12-05 人类多克隆治疗公司 对内源免疫球蛋白表达的抑制
CN103710371B (zh) 2005-08-03 2017-03-01 人类多克隆治疗股份有限公司 表达人源化免疫球蛋白的转基因动物中b细胞凋亡的抑制
JP5087625B2 (ja) 2006-09-01 2012-12-05 セラピューティック・ヒューマン・ポリクローナルズ・インコーポレーテッド 非ヒトトランスジェニック動物におけるヒトまたはヒト化免疫グロブリンの発現強化
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
AU2010303142B2 (en) * 2009-09-29 2013-05-09 Roche Glycart Ag Bispecific death receptor agonistic antibodies
PT2603530T (pt) 2010-08-13 2018-01-09 Roche Glycart Ag Anticorpos anti-fap e métodos de utilização
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
MA43017A (fr) * 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
PE20181349A1 (es) * 2015-10-07 2018-08-22 Hoffmann La Roche Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
EP3562936B1 (en) 2017-01-02 2024-05-22 F. Hoffmann-La Roche AG B-cell cultivation method
KR20220008820A (ko) * 2019-05-15 2022-01-21 쿄와 기린 가부시키가이샤 Cd40과 fap에 결합하는 이중 특이적 항체
AR121706A1 (es) * 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap

Also Published As

Publication number Publication date
WO2023117834A1 (en) 2023-06-29
CO2024008179A2 (es) 2024-07-29
AU2022423749A1 (en) 2024-06-13
IL313258A (en) 2024-08-01
TW202340248A (zh) 2023-10-16
MX2024007314A (es) 2024-06-26
CR20240246A (es) 2024-07-19
KR20240122864A (ko) 2024-08-13
PE20241754A1 (es) 2024-08-28

Similar Documents

Publication Publication Date Title
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
EA202191457A1 (ru) Анти-pd-l1/анти-4-1bb биспецифические антитела и их применения
CR20190435A (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3
CO2024008179A2 (es) Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
EA201990331A1 (ru) Мультиспецифические антигенсвязывающие белки и способы их применения
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
PE20211072A1 (es) Moleculas de union a antigeno capaces de unirse al cumulo de diferenciacion 3 (cd3) y al cumulo de diferenciacion 137 (cd137) pero no simultaneamente
CL2011003148A1 (es) Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso.
EA202190542A1 (ru) Сконструированные биспецифические белки
CL2023000499A1 (es) Proteínas que comprenden dominios de unión al antígeno de la hk2 y sus usos.
DE602006013029D1 (de) Anti-egfr-antikörper
CL2021000942A1 (es) Anticuerpos anti-npr1 y usos relacionados.
AR121706A1 (es) Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
UY37683A (es) Anticuerpo monoclonal anti-pd-l1 monoclonal
CO2021014153A2 (es) Anticuerpo monoclonal que se une específicamente a gitr
EA202191231A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ЭНДОКРИННОЙ ОФТАЛЬМОПАТИИ С ПРИМЕНЕНИЕМ АНТИ-FcRn АНТИТЕЛ
BR112022009611A2 (pt) Anticorpos anti-ror-2 e métodos de uso
PE20220763A1 (es) Materiales y metodos para modular la inmunidad mediada por celulas t
CL2020001726A1 (es) Anticuerpos monoclonales y métodos para utilizar los mismos.
PE20181199A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
PE20230602A1 (es) Anticuerpos anti-sea de muc1
BR112021020873A2 (pt) Métodos para tratamento de câncer renal com um anticorpo anti-psma/cd3
BR112022001336A8 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
CL2021001104A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20